SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-12-16 (citeline.com)
Goldman Sachs Takes Control Of Synthon
Synthon’s current owners, BC Partners, are selling a controlling stake in the Dutch complex generics specialist to Goldman Sachs Asset Management.
Read more
2024-01-25 (citeline.com)
Zydus And Synthon Sign US Ibrance Generic Deal With Potential Exclusivity
Zydus and Synthon’s entry into a high-value collaboration on palbociclib tablets is amped up with a paragraph IV certification, which may lead to a 180-day market exclusivity.
Read more
2024-01-19 (cnbctv18.com)
Zydus Life signs exclusive licensing and supply agreement for breast cancer drug
Synthon will be responsible for obtaining the US regulatory approval for the Palbociclib tablets and thereafter for the manufacturing and supply of the product.
Read more
2024-01-19 (thehindubusinessline.com)
Zydus Lifesciences subsidiary signs licensing agreement with Synthon BV
Zydus Worldwide DMCC partners with Synthon BV to manufacture and market Palbociclib tablets in the US.
Read more
2019-07-02 (businesswire.com)
BC Partners to Acquire Synthon International Holding B.V., a Global Market Leader in the Development of Complex Generics
Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached an agreement to acquire a majority stake in Sy
Read more
2012-07-18 (pwnet.nl)
License agreement between Synthon and Amgen & Watson
The Dutch pharmaceutical company Synthon has entered into a licensing agreement with Amgen and Watson regarding the drug trastuzumab. The Dutch company reports this in a news item. Synthon is developing trastuzumab as a 'biosimilar' of the drug Herceptin, a monoclonal
Read more